XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 02, 2024
Apr. 17, 2020
Jan. 02, 2019
Apr. 30, 2021
Mar. 31, 2024
Mar. 31, 2023
Collaborations with Third Parties            
First milestone payment $ 100,000          
Time required to pay cash portion 15 days          
Second milestone payment $ 25,000          
Collaboration revenue         $ 137,735 $ 24,329
Minimum            
Collaborations with Third Parties            
Aggregate payment agreement $ 125,000          
Daiichi Sankyo Europe GmbH ("DSE") | Royalty revenue and product sales bulk tablets            
Collaborations with Third Parties            
Collaboration revenue         $ 113,000 7,100
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement            
Collaborations with Third Parties            
Upfront cash payment received (paid)     $ 150,000      
Cash payment to the Company upon first commercial sales in the DSE Territory     $ 150,000      
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales     15.00%      
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales     25.00%      
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities            
Collaborations with Third Parties            
Upfront cash payment received (paid)   $ 60,000        
Potential additional future payments   $ 450,000        
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales   15.00%        
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales   30.00%        
Milestone payment, first JNDA submissions   $ 20,000        
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000        
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000        
Milestone payments related to total net sales achievements   $ 310,000        
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement            
Collaborations with Third Parties            
Collaboration revenue           $ 200
Consideration cash payment       $ 30,000    
Cash payment to be received upon certain commercial milestones       $ 175,000    
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales       5.00%    
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum            
Collaborations with Third Parties            
Percentage of royalties to be received on the net sales       20.00%